- Conditions
- Coinfection, HIV, Hepatitis C, Hiv, Substance Use Disorders
- Interventions
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced May 5, 2026, 5:54 AM EDT